Shilpa Therapeutics Private Limited - Due diligence report

A 360° intelligence report on Shilpa Therapeutics: trust score, financial health, credit view, compliance, directors, growth and distress si…

2004-04-02 Raichur, Karnataka Active Unlisted Active Compliant
Share
Connect MCP
ST Shilpa Therapeutics Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Shilpa Therapeutics — 360° Intelligence Report

Generated from MCA filings & public records
64/100
Trust Score
Moderate

Shilpa Therapeutics is assessed as Moderate with a Trust Score of 64/100. Shilpa Therapeutics is an active private limited indian non-government company incorporated in 2004, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and high financial risk profile.

Report generated on 29 Jul 2026 from the latest processed filings. Shilpa Therapeutics Private Limited snapshot & full profile →

Financial Health › Caution
Overall Assessment CautionWeakNeutralGoodStrong Good
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreModerate
64/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
85/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
5/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
45/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
60/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
55/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 45/100 Caution Indicated
  • Negative operating earnings - debt service depends on external support.
  • No open charges - unencumbered balance sheet.

Charges position: 0 open (-) · 6 satisfied (37.96 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Citi Bank N.A.2 48.0 cr
Bank Of Baroda1 48.0 cr
Axis Bank Limited1 48.0 cr
Andhra Bank2 48.0 cr
Compliance Score: 85/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • Litigation present in 1 court forum(s).
  • Delayed payments to MSME suppliers disclosed (6 disclosure(s)).
  • 1 active GST registration(s).
Legal cases on record (1)
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
RAMAKANT INNANI 01234567 Director 01/04/2018 6 yrs Approved
VISHNUKANTH CHATURBHUJ BHUTADA 01234567 Director 01/04/2018 6 yrs Approved
  • 2 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2017)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Shilpa Medicare Limited
Subsidiaries
-
Group entities
-
Capital events
6 allotment(s) · 6 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Group entityRelationship% held
Shilpa Medicare Limited Holding Company 74.00%

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 60 · Distress 55
Growth signals & trust indicators
Steady revenue growth: +38% over 4 year(s).
Operating for 22+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Negative net worth.
MSME payment delays disclosed - latest outstanding 3.79 Lakh.
1 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence70/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 2 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment43/100
Enhanced diligence advised
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance record supports lending.
Investor view42/100
Limited indicators at present
Growth quality and scalability through an investor lens.
  • 1 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
30 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
17 Aug 2023
Charge satisfied
Citi Bank N.A.
29 Nov 2022
Director ceased
RAJENDER SUNKI REDDY
30 Apr 2020
Charge satisfied
Axis Bank Limited
16 Apr 2020
Charge created
Citi Bank N.A. - 25.00 cr
Charge created
Citi Bank N.A. - 5.00 cr
31 Mar 2017
Share transfer (FY 2017)
6000.00000000 shares to Shilpa Medicare Limited
Share transfer (FY 2017)
442851.00000000 shares to Shilpa Medicare Limited
Share transfer (FY 2017)
38284.00000000 shares to Shilpa Medicare Limited
Share transfer (FY 2017)
20670.00000000 shares to Shilpa Medicare Limited
Share transfer (FY 2017)
1000.00000000 shares to Shilpa Medicare Limited
Share transfer (FY 2017)
80280.00000000 shares to Shilpa Medicare Limited
19 Dec 2016
Charge created
Axis Bank Limited - 2.00 cr
06 Jun 2016
Director ceased
VENKATESH KATAKAM
10

Key Observations

Auto-generated from the data above
Revenue grew 1.42 over the last 4 financial year(s).
Net profit margin moved from 2.1x to 24%.
Compliance record is strong - status, filings and flags are clean.
2 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
All 6 registered charge(s) stand satisfied - past borrowings repaid.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 6 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Anbr Elixir Private Limited U24304GJ2017PTC095846 Ankleshwar, Gujarat, India
B-Bond Performance Solutions Private Limited U24290HR2019PTC083532 Faridabad, Haryana, India
Suyog Pharmaceuticals Private Limited U24239MH1990PTC055025 Thane, Maharashtra, India
Peacock Allied Products Private Limited U74999MH1996PTC096681 Satara, Maharashtra, India
Koparo Clean U24239DL2021PTC383973 Delhi, Delhi, India
A.K. Bakelite And Resins Private Limited U24119DL2005PTC132098 Delhi, Delhi, India
Vasmed Health Sciences Private Limited U85110KA2015PTC082600 Bangalore Rural, Karnataka, India
Nirva Pigments Private Limited U24299GJ2019PTC109229 Ahmedabad, Gujarat, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Shilpa Therapeutics before audits and certifications: compliance score 85/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Shilpa Therapeutics: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Enhanced diligence advised. Credit risk score 45/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Limited indicators at present. Growth score 60/100, margin trends, ownership structure and peer set for Shilpa Therapeutics - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 64/100, distress signals and MSME payment-delay disclosures - know whether Shilpa Therapeutics pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Shilpa Therapeutics - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Shilpa Therapeutics an active company?

Shilpa Therapeutics has MCA status “Active” with a compliance score of 85/100 (Low Risk).

Is Shilpa Therapeutics financially healthy?

Shilpa Therapeutics has a Financial Health Score of 5/100 (Caution Indicated) based on its filed financial statements.

Should I do business with Shilpa Therapeutics?

Its overall Trust Score is 64/100 (Moderate). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Shilpa Therapeutics?

The ultimate holding entity is Shilpa Medicare Limited. 2 active director(s) are on record.

Does Shilpa Therapeutics have loans or charges against its assets?

No open charges - all 6 registered charge(s) stand satisfied, indicating past borrowings were repaid.

Is Shilpa Therapeutics up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 85/100 (Low Risk).

Is it risky to lend to Shilpa Therapeutics?

Its Credit Risk Score is 45/100 (Caution Indicated). Banker verdict: Enhanced diligence advised.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.